Business Context and Reporting Period
This Form 8-K Current Report, dated March 20, 2022, covers significant corporate governance changes at AnaptysBio, Inc. (Nasdaq: ANAB). The filing details the immediate resignation of the President and Chief Executive Officer (CEO) and the concurrent appointment of an interim CEO.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation and employment terms.
- Outgoing CEO Severance: Hamza Suria is entitled to salary continuation of $603,580 annually and COBRA premium reimbursement for 12 months.
- Interim CEO Compensation: Daniel Faga's initial annual base salary is $603,580 with a target cash bonus of up to 55% of base salary.
- Equity Grant: Mr. Faga received 887,043 restricted stock units (RSUs) vesting over 24 months.
Material Changes
The primary material change is the leadership transition effective March 20-21, 2022:
- Resignation: Hamza Suria resigned as President, CEO, and Class II Director effective immediately.
- Appointment: Daniel Faga, a Class I Director, was appointed Interim President and CEO effective March 21, 2022.
- Consulting Role: Mr. Suria will serve as a consultant for transition support through March 21, 2023, with continued equity vesting.
Guidance, Outlook, and Risks
The filing contains no financial guidance or operational outlook. It includes a standard Safe Harbor statement regarding forward-looking statements, noting that actual results may differ due to risks detailed in the Company's Annual Report on Form 10-K filed on March 7, 2022.
Contingencies and Unusual Items:
- Change in Control Provisions: Both the separation agreement for Mr. Suria and the employment agreement for Mr. Faga include accelerated vesting and enhanced severance (up to 18 months salary plus bonus) if a change in control occurs followed by termination without cause or resignation for good reason.
- Excise Tax Gross-Up: Mr. Faga's agreement includes a gross-up provision for parachute payments subject to Section 4999 excise tax.
Investor Verification Checklist
- Verify the full text of the Suria Separation Agreement and Faga Employment Agreement in the upcoming Form 10-Q for the quarter ended March 31, 2022.
- Confirm the status of the search for a permanent CEO to determine the duration of the interim arrangement.
- Review the March 7, 2022 Form 10-K for updated risk factors related to leadership stability and clinical development progress.
- Monitor the vesting schedule of the 887,043 RSUs granted to Mr. Faga and any potential dilution impact.